Page 3 - Zydus Lifesciences

Lower US growth trajectory, margin pressures ahead for Zydus Lifesciences

In the US market, robust growth in the base portfolio, new launches and generic version of Myrbetriq (for overactive bladder) aided its revenue effort in that market

Zydus enters biologics CDMO market with $125 million acquisitions

Zydus Lifesciences will acquire two US biologics manufacturing facilities from Agenus for up to $125 million, gaining immediate manufacturing capabilities and expanding its global presence

Zydus signs deal with Agenus for BOT and BAL cancer therapies in India

Zydus Lifesciences has partnered with Agenus to license the cancer immunotherapies Botensilimab and Balstilimab for India and Sri Lanka, expanding its oncology offerings

Zydus reports 17.6% rise in net profit adjusting for one-off charge

Q4FY25 profit impacted by Rs 219.6 crore goodwill impairment; adjusted profit up 17.6% while US and India businesses report double-digit revenue growth

Zydus Life Q4 profit falls 1% YoY; ₹11 dividend declared; stock down 2%

Zydus Lifesciences consolidated net profit slipped about 1 per cent year-on-year (Y-o-Y) to ₹1,171 crore in the March quarter of financial year 2025 (Q4FY25), from ₹1,182 crore in Q4FY24.

Q4 results today: NHPC, Dixon Tech, Hindalco on May 20; see full list

Q4 FY25 company results today: Zydus Lifesciences, Fortis Healthcare, and Torrent Pharma will be among 146 companies to post earnings reports for the January-March quarter

Medicines are just one part of the solution: Zydus' Sharvil Patel

Zydus MD Sharvil Patel says the company is going beyond pharma into med-tech, diagnostics, and rare diseases, aiming for a global footprint while retaining India as the manufacturing hub

USFDA issues 6 observations to Zydus' Gujarat API unit after inspection

Zydus Lifesciences on Saturday said the US health regulator has issued six observations after inspecting its Gujarat-based API manufacturing unit. "We wish to inform that the US Food and Drug Administration (USFDA) conducted a surveillance inspection at the group's API (active pharmaceutical ingredient) unit located at Dabhasa in Gujarat," the drug firm said in a regulatory filing. The inspection was conducted from April 21-25, 2025. "The inspection concluded with 6 observations and none of them were related to data integrity," Zydus Lifesciences said. The company is confident of addressing the observations expeditiously, it added.

Zydus Medtech signs deal with Brazil's Braile Biomedica for TAVI technology

To commercialise transcatheter aortic valve system in India, Europe and other select markets

Zydus, Lupin shares fall over US court ruling in Myrbetriq patent case

Companies say they are in process of assessing impact of order on operations

5 pharma stocks that you should stay away from given their tech charts

Technical charts hint that pharma shares such as Cipla, Lupin, Sun Pharma, Zydus Lifesciences and Gland Pharma could slide up to 23% as Trump tariff threat on pharma import looms.

Biocon, Cipla: Nifty Pharma down 6% as US eyes possible tariffs on sector

Adding to the worries of investors, US is looking for possible tariffs on the pharmaceutical goods

Zydus Life extends timeline for Sterling Biotech API business acquisition

The company had first disclosed the deal on September 17, 2024, after signing a business transfer agreement (BTA) with SBL

Here's why Zydus Lifesciences share price popped 3% in trade on March 19

The rise in the Zydus Lifesciences shares came after the company received final approval from the United States Food and Drug Administration (USFDA) to manufacture Apalutamide Tablets, 60 mg

Here's why Zydus Lifesciences share price was buzzing in trade on March 17

The uptick in the Zydus Life shares came after the company received final approval from the USFDA to manufacture Eluxadoline Tablets, 75 mg and 100 mg

Expanding product portfolio to drive growth for Zydus Lifesciences

The near term trigger for the stock is its plan to acquire Amplitude Surgical

Zydus Lifesciences to buy 86% stake in Amplitude Surgical for Rs 2,430 cr

Zydus will file a mandatory cash tender offer for the remaining shares of Amplitude at the same purchase price of €6.25 per share

Zydus Lifesciences to buy 86% stake in Amplitude Surgical for $280 million

Zydus Lifesciences on Tuesday said it has entered into exclusive negotiations to acquire a majority stake in France-based Amplitude Surgical for 256.8 million euros. The company has entered into negotiations with PAI Partners, Amplitude Surgical's management, as well as two minority shareholders to acquire 85.6 per cent of the company's share capital, the Ahmedabad-based drug maker said in a regulatory filing. Purchase consideration amounts to 256.8 million euros for 85.6 per cent of the outstanding shares and voting rights of Amplitude Surgical, it added. Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies. The company provides numerous value-added innovations to best meet the needs of patients, surgeons and healthcare facilities. This includes the design and development of knee and hip prostheses, which are implanted in place of damaged or worn-out joints. In fiscal year ended June 30, 2024, Amplitude Surgical generated sales of

Zydus Lifesciences shares fly 7% as USFDA okays cancer drug Dasatinib

The uptick in Zydus Life share price came after the company announced that it has received final approval from the USFDA to manufacture Dasatinib tabs, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg

Zydus launches affordable, breakthrough drug for transplant patients

Zydus Lifesciences on Wednesday said it has launched ANVIMO, a breakthrough medication for the prevention of Cytomegalovirus infection for haematopoietic stem cell transplant and kidney transplant patients. ANVIMO (Letermovir) will be available in dosages of 240 mg and 480 mg, the drug firm said in a statement. CMV infection remains one of the most serious complications in transplant patients, often leading to graft failure, decreased survival and prolonged hospital stays. Traditional CMV treatments, such as ganciclovir and valganciclovir, have notable limitations, including toxicity and bone marrow suppression. Letermovir provides a safer, well-tolerated, and effective alternative, offering superior safety and reduced side effects while improving transplant outcomes. "The introduction of ANVIMO marks a new era in bone marrow transplant and kidney transplant care in India. By making this critical therapy affordable and accessible, we are reinforcing our commitment to delivering ..